BridgeMD
Dose-finding study of LAD603 in adults with alopecia areata
EU CTIS ID: 2025-523342-27-00
What this study is testing
To evaluate the clinical efficacy of LAD603 compared with placebo in adult patients with severe to very severe alopecia areata
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subject is a male or female between 18 and 65 years old at the time of signing the informed consent.
- Subject is able to understand and willing to comply with study requirements as per Investigator’s opinion.
- Subject provides written informed consent in accordance with institutional and regulatory guidelines, prior to any study-related procedures being performed.
- AA criteria: a)Patchy scalp hair loss (including ophiasis or sisaipho variants), alopecia totalis (AT), or alopecia universalis (AU): AT is defined as complete (100%) scalp hair loss. AU is defined as complete (100%) scalp, facial, and body hair loss. b)≥50% hair loss of the scalp as measured by SALT without evidence of terminal hair regrowth within 6 months at both the Screening and Baseline (Day 1) visits. c) Current episode of hair loss lasting at least 6 months and not exceeding 7 years.
- Participants who are WOCBP or male must agree to the requirements for the avoidance of pregnancy and exposure of the participant’s partner to LAD603 during the study
You likely can't join if
- Subjects have other types of alopecia (including but not limited to traction, scarring alopecia).
- Subjects with "diffuse" type AA
- History of male or female-pattern hair loss (>Hamilton stage III or >Ludwig stage II).
- Subjects with history or presence of hair transplants.
- Use of adhesive wigs, other than banded perimeter wigs, during the study.
- Currently has an active form of other inflammatory skin disease(s) or evidence of skin condition (eg, psoriasis, seborrheic dermatitis, lupus) at the time of the Screening or Baseline (Day 1) visits that is expected to interfere with the assessment of alopecia areata severity. (For the avoidance of doubt, when no interference is expected, subjects could participate if they are otherwise eligible, including adhering to the allowed/permitted medication requirements.)
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.